These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 23999912)

  • 21. Effects of levomilnacipran extended-release on major depressive disorder patients with cognitive impairments: post-hoc analysis of a phase III study.
    Wesnes KA; Gommoll C; Chen C; Sambunaris A; McIntyre RS; Harvey PD
    Int Clin Psychopharmacol; 2017 Mar; 32(2):72-79. PubMed ID: 27861191
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Levomilnacipran: a newly approved drug for treatment of major depressive disorder.
    Mago R; Mahajan R; Thase ME
    Expert Rev Clin Pharmacol; 2014 Mar; 7(2):137-45. PubMed ID: 24524592
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Long-Term, Open-Label, Safety Study of Edivoxetine 12 to 18 mg Once Daily as Adjunctive Treatment for Patients With Major Depressive Disorder Who Are Partial Responders to Selective Serotonin Reuptake Inhibitor Treatment.
    Ball SG; Atkinson S; Sparks J; Bangs M; Goldberger C; Dubé S
    J Clin Psychopharmacol; 2015 Jun; 35(3):266-72. PubMed ID: 25815754
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Duloxetine versus escitalopram and placebo: an 8-month, double-blind trial in patients with major depressive disorder.
    Pigott TA; Prakash A; Arnold LM; Aaronson ST; Mallinckrodt CH; Wohlreich MM
    Curr Med Res Opin; 2007 Jun; 23(6):1303-18. PubMed ID: 17559729
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy and tolerability of different doses of three new antidepressants for treating major depressive disorder: A PRISMA-compliant meta-analysis.
    He H; Wang W; Lyu J; Zheng J; Guo L; An X; Fan Y; Ma X
    J Psychiatr Res; 2018 Jan; 96():247-259. PubMed ID: 29127931
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of hepatic impairment on the pharmacokinetics of levomilnacipran following a single oral dose of a levomilnacipran extended-release capsule in human participants.
    Chen L; Boinpally R; Greenberg WM; Wangsa J; Periclou A; Ghahramani P
    Clin Drug Investig; 2014 May; 34(5):351-9. PubMed ID: 24677141
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of levomilnacipran ER on fatigue symptoms associated with major depressive disorder.
    Freeman MP; Fava M; Gommoll C; Chen C; Greenberg WM; Ruth A
    Int Clin Psychopharmacol; 2016 Mar; 31(2):100-9. PubMed ID: 26584326
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effects of levomilnacipran extended-release on motivation/energy and functioning in adults with major depressive disorder.
    Thase ME; Gommoll C; Chen C; Kramer K; Sambunaris A
    Int Clin Psychopharmacol; 2016 Nov; 31(6):332-40. PubMed ID: 27455513
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A randomized, double-blind, placebo-controlled study of flexible doses of levomilnacipran ER (40-120 mg/day) in patients with major depressive disorder.
    Gommoll CP; Greenberg WM; Chen C
    J Drug Assess; 2014; 3(1):10-9. PubMed ID: 27536449
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A review of antidepressant-induced urinary hesitancy: a focus on levomilnacipran ER including two case presentations(5633).
    Asnis GM; Caneva E; Henderson MA
    Expert Opin Drug Saf; 2016 May; 15(5):717-25. PubMed ID: 26967743
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Phase I, double-blind, randomized, placebo-controlled, dose-escalation study of the effects on blood pressure of abrupt cessation versus taper down of guanfacine extended-release tablets in adults aged 19 to 24 years.
    Kisicki JC; Fiske K; Lyne A
    Clin Ther; 2007 Sep; 29(9):1967-79. PubMed ID: 18035196
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of levomilnacipran ER on noradrenergic symptoms, anxiety symptoms, and functional impairment in adults with major depressive disorder: Post hoc analysis of 5 clinical trials.
    Blier P; Gommoll C; Chen C; Kramer K
    J Affect Disord; 2017 Mar; 210():273-279. PubMed ID: 28068615
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A 12-Month Open-Label Extension Study of the Safety and Tolerability of Lisdexamfetamine Dimesylate for Major Depressive Disorder in Adults.
    Richards C; Iosifescu DV; Mago R; Sarkis E; Geibel B; Dauphin M; McIntyre RS; Weisler R; Brawman-Mintzer O; Gu J; Madhoo M
    J Clin Psychopharmacol; 2018 Aug; 38(4):336-343. PubMed ID: 29912786
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Levomilnacipran (Fetzima) for Major Depressive Disorder.
    Zaman S; McLaughlin MR
    Am Fam Physician; 2015 Oct; 92(8):727-31. PubMed ID: 26554414
    [No Abstract]   [Full Text] [Related]  

  • 35. A randomized, double-blind comparison of duloxetine and venlafaxine in the treatment of patients with major depressive disorder.
    Perahia DG; Pritchett YL; Kajdasz DK; Bauer M; Jain R; Russell JM; Walker DJ; Spencer KA; Froud DM; Raskin J; Thase ME
    J Psychiatr Res; 2008 Jan; 42(1):22-34. PubMed ID: 17445831
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Relapse prevention with gepirone ER in outpatients with major depression.
    Keller MB; Ruwe FJ; Janssens CJ; Sitsen JM; Jokinen R; Janczewski J
    J Clin Psychopharmacol; 2005 Feb; 25(1):79-84. PubMed ID: 15643103
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Safety and tolerability of desvenlafaxine in children and adolescents with major depressive disorder.
    Findling RL; Groark J; Chiles D; Ramaker S; Yang L; Tourian KA
    J Child Adolesc Psychopharmacol; 2014 May; 24(4):201-9. PubMed ID: 24611442
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Tolerability of Biphasic-Release Hydrocodone Bitartrate/Acetaminophen Tablets (MNK-155): A Phase III, Multicenter, Open-Label Study in Patients With Osteoarthritis or Chronic Low Back Pain.
    Zheng Y; Kostenbader K; Barrett T; Hisaw E; Giuliani MJ; Chen Y; Young JL
    Clin Ther; 2015 Jun; 37(6):1235-47. PubMed ID: 25913923
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The safety and tolerability of vortioxetine: Analysis of data from randomized placebo-controlled trials and open-label extension studies.
    Baldwin DS; Chrones L; Florea I; Nielsen R; Nomikos GG; Palo W; Reines E
    J Psychopharmacol; 2016 Mar; 30(3):242-52. PubMed ID: 26864543
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Preliminary experience using milnacipran in patients with juvenile fibromyalgia: lessons from a clinical trial program.
    Arnold LM; Bateman L; Palmer RH; Lin Y
    Pediatr Rheumatol Online J; 2015 Jun; 13():27. PubMed ID: 26112278
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.